Lakefront Biotherapeutics NV Stock
Stocks
LKFT
BE0003818359
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Amsterdam
11:55:00 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 23.32 EUR | +0.09% |
|
-5.20% | -16.71% |
| 08-25 | Lakefront Biotherapeutics, Gilead Secure Another Orphan Drug Designation for Skin Disorder Drug in US | MT |
| 08-24 | Lakefront Gets FDA Orphan Drug Label for Gamgertamig | MT |
| Market Cap | 1.52B 1.76B 1.43B 1.3B 2.44B 168B 2.45B 17.04B 6.55B 85.48B 6.61B 6.46B 270B | P/E 2026 * |
-13.7x | P/E 2027 * | -4.66x |
|---|---|---|---|---|---|
| Enterprise Value | -915M -1.06B -866M -785M -1.47B -101B -1.48B -10.29B -3.96B -51.62B -3.99B -3.9B -163B | EV / Sales 2026 * |
-9.65x | EV / Sales 2027 * | 0.04x |
| Free-Float |
74.64% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Amsterdam
| LKFT | Real-time | |
CBOE
| LKFT | Real-time | |
|
Boerse Muenchen
| GXE | Real-time | |
|
OTC Markets
| GLPGF | Delayed | |
|
Deutsche Boerse AG
| GXE | Delayed | |
|
London S.E.
| 0JXZ | Delayed | |
|
CBOE
| 0JXZ | Real-time | |
|
Wiener Boerse
| LKFT | End-of-day quote | |
|
Tradegate
| GXE | Real-time | |
|
Börse Stuttgart
| GXE | Delayed | |
|
Xetra
| GXE | End-of-day quote | |
|
Borsa Italiana
| 4LKFT | End-of-day quote | |
|
Xetra
| GXE | Delayed |
Last Transcript : Lakefront Biotherapeutics NV
| 1 day | +0.09% | ||
| 1 week | -5.20% | ||
| Current month | -5.05% | ||
| 1 month | -4.19% | ||
| 3 months | -6.12% | ||
| 6 months | -16.77% | ||
| Current year | -16.71% |
| 1 week | 23.16 |  | 24.58 |
| 1 month | 23.16 | | 25.73 |
| Current year | 22.32 | | 30.72 |
| 1 year | 22.32 | | 32.74 |
| 3 years | 20 | | 39 |
| 5 years | 20 | | 66.28 |
| 10 years | 20 | | 252.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Henry Gosebruch
CEO | Chief Executive Officer | 53 | 2025-05-11 |
Aaron Cox
DFI | Director of Finance/CFO | 41 | 2025-07-06 |
| Chief Operating Officer | - | 2026-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Linda Higgins
BRD | Director/Board Member | 63 | 2019-10-21 |
Oleg Nodelman
BRD | Director/Board Member | 49 | 2024-10-06 |
Henry Gosebruch
BRD | Director/Board Member | 53 | 2025-05-11 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 1/28/26 | Buy | Director | 137 | 0.0002% | ||
| 1/28/26 | Buy | Director | 375 | 0.0006% | ||
| 1/28/26 | Free | General Counsel | 235,000 | 0.3566% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.09% | -5.20% | -15.57% | -32.44% | 1.76B | |
| -0.71% | -6.35% | -4.87% | +9.03% | 45.48B | |
| +0.21% | -2.98% | +340.68% | +519.93% | 43.69B | |
| +1.74% | -2.24% | +37.28% | +21.57% | 43.09B | |
| +1.38% | -3.28% | +3.23% | +65.60% | 39.4B | |
| -1.44% | -5.26% | +8.78% | +36.85% | 31.91B | |
| +0.87% | -2.60% | - | - | 17.31B | |
| +0.75% | -0.64% | +18.07% | +110.32% | 16.4B | |
| -0.31% | -2.78% | +10.47% | +30.49% | 14.24B | |
| +1.93% | -3.55% | +74.20% | +39.37% | 13.28B | |
| Average | +0.45% | -3.74% | +52.47% | +88.97% | 26.65B | |
| Weighted average by Cap. | +0.41% | -3.68% | +72.54% | +122.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 94.87M 110M 89.82M 81.42M 153M 10.52B 154M 1.07B 410M 5.35B 414M 404M 16.91B | 80.29M 93.19M 76.03M 68.91M 129M 8.9B 130M 903M 347M 4.53B 350M 342M 14.31B |
| Net income | -40.7M -47.23M -38.53M -34.93M -65.52M -4.51B -65.86M -458M -176M -2.3B -177M -173M -7.25B | -213M -247M -201M -183M -342M -23.58B -344M -2.39B -920M -12B -927M -907M -37.91B |
| Net Debt | -2.43B -2.82B -2.3B -2.09B -3.91B -269B -3.93B -27.33B -10.51B -137B -10.59B -10.36B -433B | -1.51B -1.76B -1.43B -1.3B -2.43B -168B -2.45B -17.01B -6.54B -85.31B -6.59B -6.45B -270B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-11 | €23.32 | +0.09% | 113,875 |
| 26-09-10 | €23.30 | -2.43% | 73,501 |
| 26-09-09 | €23.88 | -0.83% | 71,157 |
| 26-09-08 | €24.08 | -1.39% | 67,106 |
| 26-09-07 | €24.42 | -0.73% | 49,928 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- LKFT Stock
Select your edition
All financial news and data tailored to specific country editions
